Jules Chong, Author at egnite

egnite 2026 Benchmark Report: Four-Class GDMT Prescribing in Systolic Heart Failure More Than Doubles, Yet Four in Five Patients Are Not Prescribed Full Guideline Therapy

October 21, 2026

Real-world data from 47 U.S. health systems shows three-year survival of 76% among systolic heart failure patients prescribed four GDMT classes, versus 52% among those prescribed none. ALISO VIEJO, Calif., Oct. 21, 2026 — egnite, Inc., a technology company advancing guideline-directed cardiovascular care and real-world evidence, today released its 2026 Benchmark Report

egnite’s Call for Science Study on M-TEER Device Durability and Long-Term Patient Outcomes to be Featured at TCT 2026

October 7, 2026

The egnite Registry contributed de-identified, longitudinal data, linking serial echocardiograms with clinical outcomes, to help answer what happens to patients after a successful mitral transcatheter edge-to-edge repair (M-TEER) procedure. ALISO VIEJO, Calif. — October 13, 2026 — egnite, Inc., a cardiovascular intelligence company that helps clinicians identify and manage patients with untreated heart disease, today announced that Dr. John T. Saxon, Director of the Advanced Cardiac Valve Center at University of Virginia

Mitral Regurgitation and Severe Aortic Stenosis: Clinical Characteristics, Prognostic Impact, and Response to TAVR: Insights From egnite Data

October 1, 2026

BACKGROUND Aortic stenosis (AS) and mitral regurgitation (MR) frequently co-occur, complicating diagnosis and treatment. We examined current US treatment trends and patient outcomes among patients with severe AS and at least moderate MR. METHODS We analyzed data from 2 992 362 patients (aged ≥18 years) undergoing 5 245 904 echocardiograms at 43 US institutions

"The future of aortic stenosis care requires proactive identification, longitudinal monitoring, and intentional pipeline management."

Rethinking the Aortic Stenosis Pipeline

September 8, 2026

Aortic stenosis care is shifting from a reactive to a proactive model. Emerging clinical evidence supports earlier identification, closer monitoring, and intentional patient management across the disease continuum. As treatment thresholds evolve, health systems need scalable approaches to identify at-risk patients, close treatment gaps, and ensure timely access to specialist

egnite Unveils Major CardioCare® Platform Improvements with a New UI that Enables Even Faster and Easier Access to Critical CV Data

September 8, 2026

The upgrade accelerates a health system’s capability to go from reactive to proactive cardiovascular care along guideline-directed treatment pathways ALISO VIEJO, Calif. — egnite, Inc., a healthcare AI company focused on helping clinicians identify and manage patients with untreated heart disease, today announced significant enhancements to its CardioCare platform, which